Emergency Medicine
Infectious Disease
Public Health, Policy, and Training

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties


The New England Journal of Medicine: Search Results in Hematology\Oncology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology\Oncology. NEJM ( is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Case 01-2018: A 39-Year-Old Woman with Rapidly Progressive Respiratory Failure
01/01/70 - Presentation of Case. Dr. Raghu R. Chivukula (Medicine): A 39-year-old woman with a history of leukemia and double-unit cord-blood transplantation was admitted to this hospital because of dyspnea, hypoxemia, and the presence of infiltrates in both lungs. Thirty months before this admission, the…

Osimertinib in Untreated EGFR-Mutated Advanced Non?Small-Cell Lung Cancer
01/01/70 - The current standard of care for patients with locally advanced or metastatic non?small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)?sensitizing mutations is treatment with a first-generation or second-generation EGFR-TKI such as…

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
01/01/70 - Immunotherapy enhances a patient?s immune system to fight disease and has recently been a source of promising new cancer treatments. Among the many immunotherapeutic strategies, immune checkpoint blockade has shown remarkable benefit in the treatment of a range of cancer types. Immune checkpoint…

Osimertinib as First-Line Treatment in EGFR-Mutated Non?Small-Cell Lung Cancer
01/01/70 - Genetic analysis is now routine in metastatic non?small-cell lung cancer (NSCLC) to identify somatic sensitizing mutations in EGFR, typically L858R and exon 19 deletion (Ex19del). Patients with these genotypes are treated with first- or second-generation epidermal growth factor receptor tyrosine…

Going from A to Z
01/01/70 - Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information, sharing his or her reasoning with the reader (regular type). The authors? commentary follows. Stage. A 70-year-old man presented to the…

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
01/01/70 - Scleroderma with internal-organ involvement (diffuse cutaneous systemic sclerosis) is a devastating autoimmune disorder. Despite advances in management, mortality driven by pulmonary involvement has not changed in 40 years. Although disease-modifying antirheumatic drugs (DMARDs) and biologics have…

Favism and Glucose-6-Phosphate Dehydrogenase Deficiency
01/01/70 - Pythagoras of Samos, a great mathematician rather than a physician, may have been first in stating emphatically, in the 5th century b.c. that fava beans could be dangerous and even lethal for humans. This gives him a place in nutrition science but not in nutrogenomics: it seems he did not realize…

Management of Sentinel-Node Metastasis in Melanoma
01/01/70 - Potential benefits of completion lymph-node dissection in patients with metastases in their sentinel lymph node include more personalized prognostic information ? and therefore more precise staging that, in turn, will influence decisions regarding adjuvant systemic therapy ? and better regional…

Making a Better Hematopoietic Stem Cell ? Timing Is Everything
01/01/70 - Allogeneic hematopoietic stem-cell (HSC) transplantation (HSCT) is a potentially lifesaving approach that is used to treat diseases ranging from congenital disorders, such as Fanconi?s anemia, to cancer. The key to any transplantation is successful donor-cell engraftment and function in the…

Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab
01/01/70 - To the Editor: We noted anaphylaxis in a patient with thrombotic thrombocytopenic purpura (TTP), which was associated with human antichimeric antibodies (HACA) to rituximab. Because of the high risk of relapse of TTP, further elective therapy was preferred. Treatment with ofatumumab, a human…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins